Home Active Agrochemical IngredientAgrochemicals SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants

SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants

by admin
0 comment
SAB Biotherapeutics

Summary :

– In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta

-SAB-185 additionally outperformed convalescent plasma

-Findings published in The Journal of Infectious Diseases

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the publication of nonclinical data from a study conducted in collaboration with the Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) Division of Viral Products highlighting that SAB-185 effectively neutralizes multiple SARS-CoV-2 strains and that it is superior to convalescent plasma in neutralizing COVID variants. SAB-185, a fully-human, specifically targeted, broadly neutralizing polyclonal antibody candidate for the treatment of high-risk non-hospitalized patients with mild to moderate COVID-19, is currently being assessed in the US National Institutes of Health (NIH) COVID-19 Phase 3 ACTIV-2 Trial.

SAB Biotherapeutics

SAB Biotherapeutics

The article, “Increased antibody avidity and cross-neutralization of SARS-CoV-2 variants by hyperimmunized Tc-Bovine derived human immunoglobulins for treatment of COVID-19,” is published in the online edition of The Journal of Infectious Diseases. SAB-185 demonstrated high antibody avidity and potency of cross-neutralizing activity in the tested variants and outperformed convalescent plasma in these assays. The study concluded that SAB-185 offers potential as a therapeutic candidate for treatment of SARS-CoV-2, including potentially addressing variants of concern.

“These promising nonclinical data, generated by the FDA, are another indicator that SAB-185 may have broad potential as an effective therapy for the treatment of COVID-19 infections across both circulating and emerging variants,” said Tom Luke, MD, Chief Medical Officer for SAB Biotherapeutics. “SAB-185 retained its ability to neutralize all of the tested SARS-CoV-2 mutant strains, and as we expected, outperformed convalescent plasma in the study.”

Dr. Luke continued, “The loss of efficacy of some current COVID-19 therapies against the prevalent Omicron strain highlights the potential of high potency, broadly neutralizing fully human polyclonal therapies such as SAB-185 against COVID-19 and other rapidly mutating viruses.”

Study researchers conducted neutralization assays with seven variant SARS-CoV-2 strains, including the Alpha, Epsilon, Iota, Gamma, Beta, Kappa and Delta strains, comparing performance of convalescent plasma from recovered COVID-19 patients against several variants of SAB-185. They evaluated antibody binding, avidity maturation, and SARS-CoV-2 virus neutralizing capacity. Compared with post-infection human convalescent plasma, SAB-185 demonstrated higher antibody avidity and more potent cross-neutralizing activity of both the variants of interest and variants of concern.The study authors concluded that SAB-185 may likely lead to effective virus neutralization and protection against previous, current and/or emerging SARS-CoV-2 strains and could potentially serve as an effective therapy for the treatment of COVID-19 patients.

In September 2021, a pre-specified interim analysis of ACTIV-2 Phase 2 data, reviewed by a Data Safety Monitoring Board, concluded that SAB-185 met the efficacy and safety criteria for advancement to the ACTIV-2 Phase 3 trial.

About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer.SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.

 

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

Lorem ipsum dolor sit amet, consect etur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis.

ChemRobotics Times

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Laest News

@2021 – All Right Reserved. Designed and Developed by Ample eBusiness

WP2Social Auto Publish Powered By : XYZScripts.com